- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02240381
Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine whether pre-transplant insulin resistance predicts for the development of new onset post-transplant diabetes mellitus (PTDM) in individuals without diabetes undergoing matched related donor (MRD) hematopoietic stem cell transplant (HCT).
II. To define the role of circulating tissue-specific Th1 cells in the development of PTDM.
III. To characterize the phenotype and function of circulating tissue-specific regulatory T cells (Tregs) in HCT recipients with or without PTDM.
OUTLINE:
Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients undergoing MRD allogeneic HCT
- DONOR: Donors undergoing stem cell collection for match related allogeneic stem cell transplant
Exclusion Criteria:
- Patients who have not received an allogeneic HCT
- Recent or current history of diabetes mellitus, defined as:1) diabetes therapy within 6 months of enrollment, or 2) fasting blood glucose at "pre-admit" (screening) visit >= 126 mg/dL
- Pregnancy or breastfeeding
- Unrelated donor, umbilical cord blood, mismatched, or haploidentical transplants
- Patients receiving T cell depletion or thymoglobulin as part of their transplant
- Patients on established, chronic corticosteroid therapy (> 5 mg /day of prednisone or prednisone equivalent) prior to transplant; established, chronic corticosteroid therapy is defined as daily dosing of > 5 mg/day of prednisone or prednisone equivalent for at least 2 weeks prior to the start of conditioning/chemotherapy or plans to continue pre-transplant corticosteroids (> 5 mg/day of prednisone or prednisone equivalent) indefinitely after transplantation
- Inability to give informed consent
- Any condition which, in the opinion of the investigator, might interfere with study objective
- Any reason which, in the opinion of the investigator, adds additional risk to the patient
- DONOR: Individuals not donating stem cells
- DONOR: Pregnancy or breastfeeding
- DONOR: Inability to give informed consent
- DONOR: Any condition which, in the opinion of the investigator, might interfere with study objective
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)
Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT.
Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
|
Korrelativa studier
During OGTT 75gm of glucose will be given followed by phlebotomy
During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Pre-transplant peripheral insulin sensitivity and glucose disposal as defined by the peripheral insulin sensitivity index among patients who do or do not go on to develop PTDM
Tidsram: Up to 21 days pre-transplant
|
Patients will be followed for 100 days after transplant for development of diabetes.
Wilcoxon rank sum test will be applied to compare the population mean difference between these two groups.
Multivariable logistic regression will evaluate whether the peripheral insulin sensitivity index is an independent predictor of PTDM after adjusting for the following covariates: fasting C-peptide level, conditioning (ablative vs. reduced intensity), or acute graft-versus-host disease (GVHD) requiring steroids.
The estimated odds ratio (OR) and 95% confidence interval of the OR will be provided to measure the effect of the association.
|
Up to 21 days pre-transplant
|
Ratio of circulating, gut-homing (alpha4beta7+) Th1 subsets pre-transplant with the development of PTDM after HCT
Tidsram: Up to day 100 after transplant
|
Wilcoxon rank sum test will be applied to compare the mean difference between these two groups.
|
Up to day 100 after transplant
|
Expression of Helios or glycoprotein A repetitions predominant in alpha4beta7+Foxp3+ Tregs versus alpha4beta7+Foxp3- conventional T cells
Tidsram: Up to day 100 after transplant
|
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups.
Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables.
|
Up to day 100 after transplant
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Changes in hepatic insulin sensitivity among patients with or without established PTDM
Tidsram: Baseline to day 90 after transplant
|
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in peripheral insulin sensitivity among patients with or without established PTDM
Tidsram: Baseline to day 90 after transplant
|
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in OGTT results among patients with or without established PTDM
Tidsram: Baseline to day 90 after transplant
|
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in hepatic insulin sensitivity in the entire cohort
Tidsram: Baseline to day 90 after transplant
|
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in peripheral insulin sensitivity in the entire cohort
Tidsram: Baseline to day 90 after transplant
|
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in OGTT results among patients in the entire cohort
Tidsram: Baseline to day 90 after transplant
|
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
|
Baseline to day 90 after transplant
|
Changes in hepatic insulin sensitivity among different groups
Tidsram: Baseline to day 90 after transplant
|
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results).
Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
|
Baseline to day 90 after transplant
|
Changes in peripheral insulin sensitivity among different groups
Tidsram: Baseline to day 90 after transplant
|
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results).
Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
|
Baseline to day 90 after transplant
|
Changes in OGTT results among different groups
Tidsram: Baseline to day 90 after transplant
|
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results).
Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
|
Baseline to day 90 after transplant
|
Ability of pre-transplant or post-transplant tissue-specific Tregs or Th1 cells to predict the development of PTDM
Tidsram: Up to day 100 after transplant
|
The comparison between independent groups, e.g., with or without PTDM or the three OGTT groups (normal, impaired glucose tolerance, or diabetic), will be carried out using either Wilcoxon rank sum test or Kruskal-Wallis test, respectively.
|
Up to day 100 after transplant
|
Insulin clamp indices
Tidsram: Up to day 100 after transplant
|
Spearman correlation will be used to evaluate the correlation between insulin clamp indices and Th1/Treg frequencies.
|
Up to day 100 after transplant
|
Th1/Treg frequencies
Tidsram: Up to day 100 after transplant
|
Spearman correlation will be used to evaluate the correlation between insulin clamp indices and Th1/Treg frequencies.
|
Up to day 100 after transplant
|
Pre-HCT Th1 and Treg tissue-specific subsets
Tidsram: Up to 100 days pre-transplant
|
Spearman correlation will evaluate the association between pre-HCT Th1 and Treg tissue-specific subsets with post-HCT donor derived Th1 and Treg.
|
Up to 100 days pre-transplant
|
Ability of alpha4beta7+ Tregs from patients with or without PTDM in suppressing the proliferation of allogeneic T cells
Tidsram: Up to day 90 after transplant
|
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups.
Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables.
Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity will be made for the parametric test such as t-test and mixed model.
If necessary, data will be transformed utilizing appropriate transformations such as the log or square root.
|
Up to day 90 after transplant
|
Ability of effector T cells from patients with PTDM to be resistant to suppression from Tregs obtained from healthy individuals
Tidsram: Up to day 100 after transplant
|
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups.
Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables.
|
Up to day 100 after transplant
|
Post-HCT donor derived Th1 and Treg subsets
Tidsram: Up to 100 days pre-transplant
|
Spearman correlation will evaluate the association between pre-HCT Th1 and Treg tissue-specific subsets with post-HCT donor derived Th1 and Treg.
|
Up to 100 days pre-transplant
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Brian Engelhardt, Vanderbilt-Ingram Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- VICC BMT 1426
- P30CA068485 (U.S.S. NIH-anslag/kontrakt)
- NCI-2014-01250 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAvslutadDiabetes mellitus | Typ 2-diabetes mellitus | Vuxendiabetes mellitus | Icke-insulinberoende diabetes mellitus | Noninsulinberoende diabetes mellitus, typ IIFörenta staterna
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Diabetes typ 1 | Typ 1-diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinberoende | Ungdomsdiabetes | Diabetes, autoimmun | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | Diabetes mellitus, spröd | Diabetes mellitus, juvenil-debut och andra villkorFörenta staterna
-
Guang NingRekryteringTyp 2-diabetes mellitus | Typ 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Läkemedelsinducerad diabetes mellitus | Andra former av diabetes mellitusKina
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Peking Union Medical College HospitalOkändTyp 2-diabetes mellitus | Typ 1-diabetes mellitus | Graviditetsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestationsdiabetes mellitus | Diabetespatienter i perioperativ periodKina
-
Leiden University Medical CenterAndaluz Health ServiceAvslutadDiabetes mellitus | Hälsobeteende | Självförmåga | Typ 2 diabetes mellitus | Typ 1 diabetes mellitusNederländerna, Spanien
-
Meir Medical CenterAvslutadDiabetes mellitus typ 2 | Diabetes mellitus, icke-insulinberoende | Diabetes mellitus, om oral hypoglykemisk behandling | Vuxen typ diabetes mellitusIsrael
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AvslutadDiabetes mellitus, typ 2 | Diabetes mellitus, typ II | Diabetes mellitus, vuxendebut | Diabetes mellitus, icke-insulinberoende | Diabetes mellitus, icke-insulinberoendeFörenta staterna
-
Medtronic DiabetesAvslutadTyp 1-diabetes mellitus | Typ 2 diabetes mellitusFörenta staterna
Kliniska prövningar på laboratoriebiomarköranalys
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
Progenity, Inc.AvslutadDowns syndrom | Aneuploidi | DiGeorges syndrom | Turnersyndrom | Klinefelters syndrom | Kromosomradering | Edwards syndrom | Pataus syndromFörenta staterna
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadOkändYrkesmässig exponering | Muskuloskeletala sjukdomarChile
-
Healthy.io Ltd.Avslutad
-
Modarres HospitalAvslutadKomplikationer | Bildvägledd biopsi | Njure GlomerulusIran, Islamiska republiken
-
Assistance Publique - Hôpitaux de ParisHar inte rekryterat ännuCochleaimplantation | Grundlig medfödd dövhetFrankrike
-
Duke UniversityIndragenAntikoagulations- och trombostest (AT-POCT)Förenta staterna